Press releases
Apr 15, 2024
Actimed Therapeutics to Present at BioTrinity 2024
Oct 19, 2023
Actimed Therapeutics Appoints Martin Walton as Chief Financial Officer
Sep 7, 2023
Actimed Therapeutics announces FDA approval of its Investigational New Drug application for Phase 2b/3 IMPACT clinical trials of S-pindolol benzoate to treat cancer cachexia
Aug 22, 2023
Actimed Therapeutics secures additional £4.75m funding in Series A extension round, almost doubling Series A proceeds
Jun 26, 2023
Actimed Therapeutics closes over-subscribed Series A Financing Round of £5 million to advance clinical development of lead programme for cancer cachexia
Jun 19, 2023
Actimed Therapeutics Chief Medical Officer Frank Misselwitz Presents at 16th International Conference of the Society on Sarcopenia, Cachexia and Wasting Disorders
Jan 4, 2023
Actimed Therapeutics successfully closes second tranche of £10m seed financing to progress pipeline for treatment of cancer cachexia and other muscle wasting disorders
Jan 2, 2023
Actimed Therapeutics to Present Company Progress at Biotech Showcase 2023 in San Francisco
Jun 23, 2022
Actimed Therapeutics to present on development of its lead asset in treatment of cancer cachexia at the Society on Sarcopenia, Cachexia and Wasting Disorders
May 12, 2022
Actimed Therapeutics’ Company participation and panel discussion at LSX World Congress 2022
May 4, 2022
Actimed Therapeutics secures significant new patent, extending IP coverage of its lead compound for use in key indication
Jan 10, 2022
Actimed Therapeutics to Participate at Biotech Showcase 2022
Dec 14, 2021
Actimed Therapeutics Achieves Major Corporate Milestone – Initiation of first clinical study of new salt of S-pindolol (ACM-001.1)
Oct 13, 2021
Actimed Therapeutics Continues to Strengthen Intellectual Property Portfolio with Newly Granted US and Canadian Patents
Jun 10, 2021
Actimed Therapeutics Announces Successful Closing of £2.5m Extended Seed B Funding Round
Jun 9, 2021
Actimed Therapeutics to Present at BioTrinity 2021
Apr 13, 2021
Actimed Therapeutics and Faraday Pharmaceuticals Announce License Agreement for S-oxprenolol
Feb 2, 2021
Actimed Therapeutics Appoints Frank Misselwitz MD, PhD as Chief Medical Officer
Dec 1, 2020
Actimed Therapeutics Granted Broad US Patent Covering Rights to ACM–002 (S-oxprenolol) for Treating Cancer Cachexia
Nov 23, 2020
Actimed Therapeutics Licenses Additional European Patent Rights to S-oxprenolol in ALS from Charité – Universitätsmedizin Berlin
Oct 22, 2020
Actimed Therapeutics to present at upcoming Bio-Europe conference as one of 'Scrip’s 10 to watch'
Sep 2, 2020
Actimed Therapeutics appoints Dr Chika Yoshinaga as Development, Partnering and Financing Advisor in Japan and China
Apr 2, 2020
Actimed Therapeutics appoints Annalisa Jenkins as Advisor
Oct 30, 2019
Actimed Therapeutics appoints Robin Bhattacherjee as CEO
Oct 31, 2018
Actimed Therapeutics, the Cachexia Company, Raises £1.25m in Seed A Round
Apr 5, 2018
Actimed Therapeutics appoints pharma veteran Dr David Ebsworth as Chairman